Application of combined catechin matters together with antibacterial agents

A technology of catechins and antibacterial drugs is applied in the directions of antibacterial drugs, medical preparations containing active ingredients, pharmaceutical formulas, etc. , to achieve the effect of improving antibacterial efficacy and reducing the abuse of antibacterial drugs

Inactive Publication Date: 2011-10-05
ARMY MEDICAL UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported in the literature that the combination of a catechin substance and antibiotics can be used in the treatment of MRSA, but the effect is not good, which limits the promotion of catechin substances in the application of antibacterial sensitization

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combined catechin matters together with antibacterial agents
  • Application of combined catechin matters together with antibacterial agents
  • Application of combined catechin matters together with antibacterial agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] This example is to study the MIC (Minimum Inhibitory Concentration) and MBC (Minimum Bactericidal Concentration) of catechins and various β-lactam antibiotics on MRSAWHO-2.

[0034] Using the microwell dilution method, adjust the bacterial concentration to 10 5CFU / ml, inoculated in a 96-well sterile culture plate. C, ECG, EGC, penicillin sodium, ampicillin and other 13 kinds of drugs were diluted to 5.12mg / ml with normal saline respectively. Add various drugs into the culture wells containing bacteria, and serially dilute, the final concentrations of drugs in the 1st to 11th wells are 512, 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5ug / ml. Incubate in a 37°C incubator for 24h and 48h, read the positive and negative control wells, the negative control wells are clear, and the positive control wells are turbid. The MIC of a drug on bacteria is the lowest drug concentration that inhibits the growth of bacteria visible to the naked eye after 24 hours, and the MBC of the drug o...

Embodiment 2

[0038] This example is to study the influence of C, ECG, EGC and OXA respectively on MRSA WHO-2MIC and MBC.

[0039] Using the checkerboard microwell dilution method, adjust the bacterial concentration to 10 5 CFU / ml, inoculated in a 96-well sterile culture plate, and observed the MIC and MBC of the compatible drugs on WHO-2. The results of this experiment showed that the combined application of C, ECG, and EGC with OXA could not significantly reduce the MIC and MBC of antibacterial drugs, or only had a low sensitization effect (such as OXA+C 64 μg / ml, OXA+ECG 16 μg / ml). ml, FICI are both 0.5). (See Table 2).

[0040] Table 2 OXA MIC / MBC after synergy of C, ECG, EGC and OXA respectively

[0041]

Embodiment 3

[0043] This example is to study the effect of C and ECG, C and EGC two-drug combination or C, ECG and EGC three-drug combination combined with OXA on MRSA WHO-2 MIC.

[0044] Using the checkerboard microwell dilution method, adjust the bacterial concentration to 10 5 CFU / ml, inoculated in a 96-well sterile culture plate, and observed the MIC of the compatible drug on WHO-2. The results of this experiment showed that although C, ECG, and EGC alone, or combined with OXA, could not reduce the MIC of antibacterial drugs, the combination of C and ECG, C and EGC, or the combination of C, ECG and EGC The MIC of MRSA WHO-2 can be significantly reduced after combined application with OXA. (See Table 3, 4, 5)

[0045] Table 3 MIC (μg / ml) of antibacterial drugs against MRSA WHO-2 when different concentrations of C combined with ECG and OXA were used together

[0046]

[0047]

[0048] Table 4 MIC (μg / ml) of antibacterial drugs against MRSA WHO-2 when different concentrations of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of combination of two or three of catechin matters with antibiotics in preparing antibacterial agents. The combined catechin matters applied to the field of anti-methicillin-resistant staphylococcus aureus (MRSA) together with antibiotics provides antibacterial and sensitivity enhancing effects of medicaments, so that the application of the catechin matters iswidened, the application scheme of the catechin matters is widened, and the phenomenon that the MRSA resists medicaments due to antibacterial agent abuse can be lightened.

Description

technical field [0001] The invention relates to the field of medicine application, in particular to the application of combining any two or three of catechin and epigallocatechin or epicatechin gallate with antibiotics in the preparation of antibacterial medicines. Background technique [0002] Since the first strain of Methicillin-resistant Staphylococcus aureus (MRSA) was discovered in 1961, MRSA has become an important pathogen of hospital infection worldwide since the 1980s. MRSA has varying degrees of drug resistance to β-lactam antibiotics such as penicillins, cephalosporins and cephamycins, aminoglycosides, quinolones and even glycopeptides. Therefore, it is urgent to find ways to overcome drug resistance mechanisms, discover new targets and develop new antibiotics. [0003] The drug resistance of MRSA is mainly related to the production of a special penicillin-binding protein 2a (PBP2a) with low affinity, which can replace several other PBPs inhibited by antibiotics...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/546A61K31/431A61K31/43A61P31/04A61K31/353
Inventor 周红郑江覃容欣肖康康蒋为薇李斌
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap